Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Suboptimal Clinical Response to Anti-tumor Necrosis Factor alpha (TNFa) Antibody Therapy in a Patient with Severe Rheumatoid Arthritis and Lymphadenopathy: CASE REPORT
Ist Teil von
Scandinavian journal of rheumatology, 1998, Vol.27 (4), p.303-305
Ort / Verlag
Informa UK Ltd
Erscheinungsjahr
1998
Quelle
Taylor & Francis Journals Auto-Holdings Collection
Beschreibungen/Notizen
This concerns a patient with severe rheumatoid arthritis (RA) and lymphadenopathy (LA) who showed suboptimal clinical response to anti-tumor necrosis factor alpha (TNFalpha) antibody (Ab), cA2 therapy. The assessment of TNFalpha and IL-6 mRNA expression in the swollen lymphnode (LN) of the patient by reverse transcription, polymerase chain reaction (RT-PCR) before cA2 treatment, showed only enhanced IL-6 production, but not TNFalpha. Moreover, cA2 failed to inhibit in-vitro spontaneous IL-6 production in the LN block culture from the patient. Taken together, these results indicate that IL-6 production in the swollen LNs of the patient might not depend on TNFalpha. This might partly cause suboptimal clinical response to anti-TNFalpha Ab therapy in the patient.